Replagal IV 3.5mg, containing Agalsidase alpha (genetically recombinant), is manufactured by Takeda Pharmaceutical. This injectable drug, with YJ code 3959410A1025 and standard 3.5mg x 3.5mL x 1 bottle, is an enzyme replacement therapy for Fabry disease, working to break down accumulated fat molecules.
Replagal IV 3.5mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).